Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) and Hypermarcas (OTCMKTS:HYPMY – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.
Valuation & Earnings
This table compares Gyre Therapeutics and Hypermarcas”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gyre Therapeutics | $110.06 million | 4.29 | $5.03 million | ($0.20) | -21.15 |
| Hypermarcas | $1.38 billion | 2.04 | $213.10 million | $0.50 | 8.00 |
Hypermarcas has higher revenue and earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Hypermarcas, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
24.0% of Gyre Therapeutics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Gyre Therapeutics and Hypermarcas, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gyre Therapeutics | 1 | 1 | 0 | 0 | 1.50 |
| Hypermarcas | 0 | 1 | 0 | 1 | 3.00 |
Volatility & Risk
Gyre Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Hypermarcas has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Profitability
This table compares Gyre Therapeutics and Hypermarcas’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gyre Therapeutics | -14.80% | -7.39% | -5.74% |
| Hypermarcas | 19.77% | 12.68% | 6.78% |
Summary
Hypermarcas beats Gyre Therapeutics on 9 of the 13 factors compared between the two stocks.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.
About Hypermarcas
Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo Química and Mantecorp.
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
